206 related articles for article (PubMed ID: 31472672)
1. Alteration of tumor associated neutrophils by PIK3CA expression in endometrial carcinoma from TCGA data.
Pan Y; Jia LP; Liu Y; Han Y; Deng Q
J Ovarian Res; 2019 Aug; 12(1):81. PubMed ID: 31472672
[TBL] [Abstract][Full Text] [Related]
2. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
Front Immunol; 2021; 12():788431. PubMed ID: 34970268
[TBL] [Abstract][Full Text] [Related]
3. Expression and clinical significance of PD-1 in UCEC and its Impact on tumor.
Xing F; Yang Y; Zheng W
Cell Mol Biol (Noisy-le-grand); 2023 May; 69(5):168-173. PubMed ID: 37571885
[TBL] [Abstract][Full Text] [Related]
4.
Holst F; Werner HMJ; Mjøs S; Hoivik EA; Kusonmano K; Wik E; Berg A; Birkeland E; Gibson WJ; Halle MK; Trovik J; Cherniack AD; Kalland KH; Mills GB; Singer CF; Krakstad C; Beroukhim R; Salvesen HB
Clin Cancer Res; 2019 Jan; 25(1):334-345. PubMed ID: 30442683
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of ESRRA in Endometrial Cancer.
Wang S; Huo X
Technol Cancer Res Treat; 2021; 20():1533033821992083. PubMed ID: 33525981
[TBL] [Abstract][Full Text] [Related]
6. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
8.
Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
[TBL] [Abstract][Full Text] [Related]
9. A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.
Zhou M; Zhang Z; Zhao H; Bao S; Sun J
BMC Cancer; 2018 Jan; 18(1):39. PubMed ID: 29304762
[TBL] [Abstract][Full Text] [Related]
10. LINC01589 serves as a potential tumor-suppressor and immune-related biomarker in endometrial cancer: A review.
Chen R; An J; Wang Y; Yang L; Lin Q; Wang Y
Medicine (Baltimore); 2023 Apr; 102(15):e33536. PubMed ID: 37058060
[TBL] [Abstract][Full Text] [Related]
11. MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma.
Chen J; Wu S; Wang J; Han C; Zhao L; He K; Jia Y; Cui M
J Cell Mol Med; 2023 Jun; 27(12):1708-1724. PubMed ID: 37246638
[TBL] [Abstract][Full Text] [Related]
12. RNF183 Is a Prognostic Biomarker and Correlates With Tumor Purity, Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
Geng R; Zheng Y; Zhao L; Huang X; Qiang R; Zhang R; Guo X; Li R
Front Genet; 2020; 11():595733. PubMed ID: 33324448
[TBL] [Abstract][Full Text] [Related]
13. Relationship between Prognosis, Immune Infiltration Level, and Differential Expression of PARVG Gene in Uterine Corpus Endometrial Carcinoma.
Wang F; Bi J; Yi C; Zhang Y; Zhang Y; Yue Q
Contrast Media Mol Imaging; 2022; 2022():7376588. PubMed ID: 35655721
[TBL] [Abstract][Full Text] [Related]
14. Pan-Cancer Gene Analysis of m6A Modification and Immune Infiltration in Uterine Corpus Endometrial Carcinoma.
Xie BF; Xia Y; Lin DH; Lian B; Zhang ML; Liu L; Qin CR
Comput Intell Neurosci; 2022; 2022():6530884. PubMed ID: 36199963
[TBL] [Abstract][Full Text] [Related]
15. Mammaglobin B may be a prognostic biomarker of uterine corpus endometrial cancer.
Li J; Xu W; Zhu Y
Oncol Lett; 2020 Nov; 20(5):255. PubMed ID: 32994818
[TBL] [Abstract][Full Text] [Related]
16. Signal transducer and activator of transcription family is a prognostic marker associated with immune infiltration in endometrial cancer.
Zhou XY; Dai HY; Zhang H; Zhu JL; Hu H
J Clin Lab Anal; 2022 Apr; 36(4):e24315. PubMed ID: 35244291
[TBL] [Abstract][Full Text] [Related]
17. Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma.
Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
Cancer Med; 2018 Nov; 7(11):5632-5642. PubMed ID: 30306731
[TBL] [Abstract][Full Text] [Related]
18. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma.
Zhou C; Li C; Yan F; Zheng Y
Cancer Cell Int; 2020 Nov; 20(1):541. PubMed ID: 33292199
[TBL] [Abstract][Full Text] [Related]
19. [Dysregulation of MAD2L1/CAMK2A/PTTG1 Gene Cluster Maintains the Stemness Characteristics of Uterine Corpus Endometrial Carcinoma].
Zheng J; Zhang YW; Pan ZF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):685-695. PubMed ID: 34728029
[TBL] [Abstract][Full Text] [Related]
20. CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma.
Wang G; Fu J; Liu M; Zheng Q
PLoS One; 2024; 19(1):e0277872. PubMed ID: 38232115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
